Stem Cell Therapy Market Size, Share, Global Future Trend, Segmentation, Business Growth, Top Key Players, Opportunities and Forecast to 2027 – Owned

New Jersey, United States,- The latest report published by Market Research Intellect on Stem Cell Therapy Market provides crucial market insights along with detailed segmentation analysis. The report examines key driving factors that are expected to drive the growth of the market.

Global Stem Cell Therapy Market Research Report gives knowledgeable information on various market situations, for example, potential development factors, factors controlling the development, market opportunities, and dangers to the worldwide market. Also, the report broadly centers around the competitive analysis of Stem Cell Therapy Market. The competitive analysis segment incorporates key manufacturers, fresh players, providers, market strategies, potential chances, operation landscape, and analysis of the trends of the Stem Cell Therapy market. The market results are centered around the current market scenario. To gauge and predict the degree of competition in this market. This report will likewise support all the manufacturers and speculators to have a superior comprehension of the investments to know where the market is heading.

Key highlights from COVID-19 impact analysis:

Unveiling a brief about the Stem Cell Therapy market competitive scope:

The report includes pivotal details about the manufactured products, and in-depth company profile, remuneration, and other production patterns.

The research study encompasses information pertaining to the market share that every company holds, in tandem with the price pattern graph and the gross margins.

Stem Cell Therapy Market, By Type

Stem Cell Therapy Market, By Application

Other important inclusions in the Stem Cell Therapy market report:

A brief overview of the regional landscape:

Reasons To Buy:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See the article here:
Stem Cell Therapy Market Size, Share, Global Future Trend, Segmentation, Business Growth, Top Key Players, Opportunities and Forecast to 2027 - Owned

UPDATED: Moderna offers steep discount in US supply deal but still takes the crown with close to $2.5B in vaccine contracts – Endpoints News

BioNTech execs say theyre on track to get their late-stage data on a Covid-19 vaccine partnered with Pfizer into the hands of regulators as early as October.

In their Q2 release Tuesday morning, the biotech reported that investigators could have late-stage data as early as October, and they wont be wasting any time in hustling that over to the FDA.

I am incredibly proud of our team, who has worked tirelessly to initiate our BNT162 Phase 2b/3 trial in record time and put us in a position to seek regulatory review as early as October of this year, if our trials are successful, said Ugur Sahin, BioNTechs CEO and co-founder.

Unlock this story instantly and join 87,500+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

More:
UPDATED: Moderna offers steep discount in US supply deal but still takes the crown with close to $2.5B in vaccine contracts - Endpoints News

Cell Therapy Technologies Market Research Report by Product, by Process, by Cell Type, by End User – Global Forecast to 2025 – Cumulative Impact of…

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- Cell Therapy Technologies Market Research Report by Product (Consumables, Equipment, and Systems & Software), by Process (Cell Preservation, Distribution, and Handling, Cell Processing, and Process Monitoring and Quality Control), by Cell Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 Read the full report: https://www.reportlinker.com/p05913782/?utm_source=PRN

The Global Cell Therapy Technologies Market is expected to grow from USD 11,492.28 Million in 2019 to USD 24,683.74 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 13.58%.

Market Segmentation & Coverage: This research report categorizes the Cell Therapy Technologies to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Cell Therapy Technologies Market studied across Consumables, Equipment, and Systems & Software. The Equipment further studied across Cell Processing Equipment and Single-Use Equipment.

Based on Process, the Cell Therapy Technologies Market studied across Cell Preservation, Distribution, and Handling, Cell Processing, and Process Monitoring and Quality Control.

Based on Cell Type, the Cell Therapy Technologies Market studied across Animal Cells and Human Cells. The Human Cells further studied across Differentiated Cells and Stem Cells.

Based on End User, the Cell Therapy Technologies Market studied across Life Science Research Companies and Research Institutes.

Based on Geography, the Cell Therapy Technologies Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Therapy Technologies Market including Beckman Coulter, Inc., Becton, Dickinson and Company, Ge Healthcare, Lonza Group, Merck KGaA, Miltenyi Biotec GmbH, Sartorius, Stemcell Technologies, Terumo Bct, Inc., and Thermo Fisher Scientific, Inc..

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cell Therapy Technologies Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Cell Therapy Technologies Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Therapy Technologies Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Therapy Technologies Market? 4. What is the competitive strategic window for opportunities in the Global Cell Therapy Technologies Market? 5. What are the technology trends and regulatory frameworks in the Global Cell Therapy Technologies Market? 6. What are the modes and strategic moves considered suitable for entering the Global Cell Therapy Technologies Market?

Read the full report: https://www.reportlinker.com/p05913782/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/cell-therapy-technologies-market-research-report-by-product-by-process-by-cell-type-by-end-user---global-forecast-to-2025---cumulative-impact-of-covid-19-301110784.html

SOURCE Reportlinker

View original post here:
Cell Therapy Technologies Market Research Report by Product, by Process, by Cell Type, by End User - Global Forecast to 2025 - Cumulative Impact of...

Lung cancer mortality reduction linked to improvements in targeted therapies – 2 Minute Medicine

1. In this retrospective cohort study, there was an observed decrease in mortality in non-small-cell lung cancer patients that corresponded with the approval of targeted therapies

2. The improved mortality of small cell lung cancer was not driven by treatment advancement but rather a decrease in the incidence

Evidence Rating Level: 2 (Good)

Study Rundown: Lung cancer is the deadliest cancer in the United States. It can be divided into two histological subtypes: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Using the U.S. Surveillance, Epidemiology, and End Results (SEER) database, the authors in this study analyzed mortality trends attributed to the specific histological subtype of lung cancer termed incidence-based mortality. For men and women with NSCLC, incidence and incidence-based mortality decreased, with a greater mortality decrease from 2013-2016 corresponding with an improvement in survival from diagnosis. For SCLC, incidence and incidence-based mortality decreased but with no improvement in survival from diagnosis. Notably, the authors point out that EGFR targeted therapies were approved in 2013 which corresponds to the increase in survival in NSCLC. There should be caution in the interpretation in the studys suggestion that the survival benefit is entirely driven by targeted therapies as there is no direct data on the number of patients treated with EGFR targeted therapies right after 2013. However, the results of these study are generalizable given that it encompassed diverse demographics which showed consistent trends across race and gender subgroups and adequate follow-up data.

Click here to read the study, published today in NEJM

Relevant Reading: Updated statistics of lung and bronchus cancer in United States (2018)

In-Depth [retrospective cohort]: In this retrospective cohort study, lung cancer incidence and lung cancer linked deaths were analyzed in the SEER cancer registry from 2001 to 2016. For NSCLC, in men, the annual incidence decreased by 1.9% from 2001 to 2008, and then by 3.1% from 2008 to 2016. Incidence-based mortality decreased by 3.2% annually from 2006 to 2013 and then decreased by 6.3% from 2013 to 2016. Among women, 2001-2006 incidence did not change significantly, while from 2006-2013 incidence decreased by 1.5% annually. Incidence-based mortality decreased by 2.3% from 2006 to 2014, and then by 5.9% from 2014-2016. 2-year survival improved from 35% in 2001 to 44% in 2014 for women and went from 25% to 35% for men. For SCLC from 2001-2016, in men, the incidence decreased by 3.6%, while incidence-based mortality decreased by 4.3%. For women, the incidence decreased by 2.7% and incidence-based mortality decreased by 3.7%. 2-year survival from 2001 vs. 2016 was 12% and 11% for men and 14% and 17% for women. Taken together, these results indicated that mortality decreases in NSCLC were likely driven by improved survival, and for SCLC, it was mainly driven by decreased incidence.

Image: PD

2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Read more:
Lung cancer mortality reduction linked to improvements in targeted therapies - 2 Minute Medicine

Animal Stem Cell Therapy Sales Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast to…

New Jersey, United States,- The most recent Animal Stem Cell Therapy Sales Market Research study includes some significant activities of the current market size for the worldwide Animal Stem Cell Therapy Sales market. It presents a point by point analysis dependent on the exhaustive research of the market elements like market size, development situation, potential opportunities, and operation landscape and trend analysis. This report centers around the Animal Stem Cell Therapy Sales business status, presents volume and worth, key market, product type, consumers, regions, and key players.

The COVID-19 pandemic has disrupted lives and is challenging the business landscape globally. Pre and Post COVID-19 market outlook is covered in this report. This is the most recent report, covering the current economic situation after the COVID-19 outbreak.

Key highlights from COVID-19 impact analysis:

Unveiling a brief about the Animal Stem Cell Therapy Sales market competitive scope:

The report includes pivotal details about the manufactured products, and in-depth company profile, remuneration, and other production patterns.

The research study encompasses information pertaining to the market share that every company holds, in tandem with the price pattern graph and the gross margins.

Animal Stem Cell Therapy Sales Market, By Type

Animal Stem Cell Therapy Sales Market, By Application

Other important inclusions in the Animal Stem Cell Therapy Sales market report:

A brief overview of the regional landscape:

Reasons To Buy:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Digital Imaging Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Driveline Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Environment, Health And Safety Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Glamping Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Photogrammetry Software Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Original post:
Animal Stem Cell Therapy Sales Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast to...

Stem Cell Alopecia Treatment Market 2020 analysis with Key Players, Applications, Future Trends and Forecasts by 2027 – Chelanpress

Competitive Landscape of the Stem Cell Alopecia Treatment Market:

The Market for the Stem Cell Alopecia Treatment Market industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Regional Analysis of Global Stem Cell Alopecia Treatment Market:

The report offers a comprehensive breakdown of the regional analysis of the market and subsequent country-wise analysis. The regional analysis of the market comprises of production volume information, consumption volume and patterns, revenue, and growth rate for the forecast period of 2020-2027. According to the regional analysis, the market is primarily spread over key geographical regions such as North America (U.S.A, Canada, and Mexico), Europe (Germany, Italy, Spain, UK, and Rest of EU), Asia Pacific (India, Japan, China, South Korea, and Rest of APAC), Latin America (Brazil, Chile, Peru, Argentina, and Rest of Latin America), and Middle East & Africa (Saudi Arabia, South Africa, and Rest of MEA).

Highlights of the TOC of the Global Stem Cell Alopecia Treatment Market Report:

Ask For [emailprotected] https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=CPN&utm_medium=003

The scope of the Report:

The report offers a complete company profiling of leading players competing in the Global Stem Cell Alopecia Treatment Market with a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the Global Stem Cell Alopecia Treatment Market.

Our research Data provides answers to the following key questions:

Purchase report with detailed assessment of the present and future impact of the COVID-19 pandemic on the industry: https://www.verifiedmarketresearch.com/checkout/?buyreport=15102&utm_source=CPN&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080

UK: +44 (203)-411-9686

APAC: +91 (902)-863-5784

US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

More here:
Stem Cell Alopecia Treatment Market 2020 analysis with Key Players, Applications, Future Trends and Forecasts by 2027 - Chelanpress

Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With…

NEW YORK and LONDON, Aug. 12, 2020 (GLOBE NEWSWIRE) --Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces a successful End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) regarding Akaris proposed pivotal Phase III program for the treatment of BP.

The FDA has agreed to a two-part pivotal trial with Part A and Part B having the same structure, duration, endpoints and target population of moderate and severe BP patients.

In the Phase III study, patients will be randomized to receive either nomacopan plus oral corticosteroids (OCS) or placebo plus OCS. Following an initial stabilization phase, the steroids will be tapered according to disease response to a minimal level of OCS (< 0.1mg/kg/d prednisone or equivalent) which is considered safe. If disease response is rapid, as was seen in the nomacopan Phase II study in patients with BP, OCS could be tapered to the minimal level within six weeks. The goal of conventional OCS tapering is to achieve minimal therapy (prednisone <0.1mg/kg/day) within four to six months after initiation of treatment1. Patients will only have their OCS tapered if their disease continues to respond to treatment as the OCS dose is decreased.

Once patients are on minimal OCS plus either nomacopan or placebo, the primary endpoint will be achieved by those patients with complete disease remission for eight weeks or longer. The duration of the study is six months after which patients may be eligible to enter a separate one-year long-term safety study to provide at least six months of additional safety data.

Part A of the study is the same design as Part B but smaller and with the objective of comparing the Companys target dose (comparable to dosing used in the Companys hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and paroxysmal nocturnal hemoglobinuria (PNH) Phase III programs) with a lower dose of nomacopan and with placebo. Following Part A and discussion with the FDA, Part B will be conducted at the same trial sites using the optimal dose from Part A.

Clive Richardson, Chief Executive Officer of Akari Therapeutics, said, Following our positive Phase II study, we are very pleased that the FDA has agreed with the pivotal study design and provided a clear pathway to a potential approval for nomacopan in patients with BP. Success in this study would also open up a range of other dermatological conditions with related pathology.

Russell P. Hall, M.D., Professor of Dermatology, Duke University School of Medicine, who attended Akaris EOP2 meeting, said, These proposed studies are expected to provide the critical data needed to assess the efficacy of nomacopan in providing rapid control of the inflammation in the skin of patients with bullous pemphigoid and minimize the need for high dose systemic corticosteroids in this very vulnerable patient population.

1Feliciani et al (2015)

Background on Bullous Pemphigoid (BP)

BP is a severe orphan autoimmune inflammatory blistering skin disease with no approved treatments in the U.S. and Europe. This chronic disease may last several years in the absence of treatment and has a tendency to relapse. BP is most common in the elderly and is primarily treated with steroids and immunosuppressants for six months or more which bring with them deleterious side effects and an approximately three-fold increase in mortality in the BP treated population. The prevalence of BP is estimated to be over 100,000 patients in U.S. and Europe.

In BP patients there is evidence that both terminal complement activation (via complement component C5) and the lipid mediator leukotriene B4 (LTB4) have a central role in driving the disease. Ex vivo data in BP patients, published in the August 2019 edition of JCI Insight [LINK], showed a pronounced accumulation of LTB4 and C5 and its activation products in the inflamed skin of BP patients. This underlies the rationale for treatment with nomacopan which is a unique bifunctional inhibitor of both C5 and LTB4 and a range of downstream cytokines. In addition to BP, the Company believes this unique mode of action underpins the activity of nomacopan across the Companys other target conditions TMA-HSCT, COVID pneumonia and ophthalmology.

AboutAkari Therapeutics Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.

Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance upon the Companys forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this press release. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product candidates and unexpected costs that may result therefrom; difficulties enrolling patients in our clinical trials; our ability to enter into collaborative, licensing, and other commercial relationships and on terms commercially reasonable to us; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected; risks associated with the impact of the outbreak of coronavirus; risks associated with the SEC investigation; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Investor Contact:

Peter Vozzo Westwicke +1 (443) 213-0505 peter.vozzo@westwicke.com

Media Contact:

Sukaina Virji/Lizzie Seeley Consilium Strategic Communications +44 (0)20 3709 5700 Akari@consilium-comms.com

See the article here:
Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With...

The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline – Endpoints News

When Infinity put up duvelisib for a no-money-down instant deal, the biotech was looking for a quick exit from a clinical disaster. AbbVie had walked away from their alliance after looking at how the data stacked up in a crowded field.

And while it was approvable, it wasnt looking pretty to anyone who thought in commercial terms.

One Big Pharmas trash, though, was seen as a biotech treasure as a deeply troubled Verastem stepped up to grab the PI3K-delta/gamma promising to run it across the goal lines at the FDA. And they did just that, only with little to show for it.

Now, after racking up just $12 million in product sales last year, its Verastems turn to walk away only they get $70 million in cash for the underperforming cancer therapeutic, with a chance to add $200 million-plus if the new owner can make a success of it.

Secura Bio now counts itself as the owner of the drug, sold as Copiktra. And Secura will add up to $45 million in milestones if the drug is approved in the US and Europe for peripheral T-cell lymphoma. Theres $50 million if Secura can push sales over the $100 million annual sales level, which also comes with low double-digit royalties over that $100 million mark.

Verastem now wants to create a string of catalysts to whet investors interest in its RAF/MEK inhibitor VS-6766 for low grade ovarian cancer and a FAK inhibitor defactinib program in KRAS mutant tumors. Investigators are focused on KRAS G12V, part of a busy field after Amgen opened up things with positive data for NSCLC. Registration-directed Phase II trials get underway before the end of this year.

Verastem lost about $149 million last year, as it took its total burn past the half-billion dollar mark. Brian Stuglik, an Eli Lilly vet, jumped on as CEO a year ago, replacing Robert Forrester. Now Stugliks team is betting that this time theyre going to get it right. Or at least as good as it gets.

Read the original here:
The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline - Endpoints News

FDA warns businesses to stop claiming to prevent, treat and diagnose COVID-19 – wtkr.com

HAMPTON ROADS, Va. - The FDA is warning that companies are preying on the fears people have about COVID-19 and producing products that they say help prevent, treat, diagnose and cure COVID-19.

The FDA says the claims are false and not scientifically proven.

The FDA says as of August 10, 102 warning letters have been sent to businesses stating that if they dont make changes to the false claims within 48 hours, they will be subject to legal action.

The products include pills, sprays, essential oils, stem cell products and even home COVID-19 kits.

I think this is a moment where they're rising to the challenge and they're doing quite a good job in terms of tracking down businesses that are making non evidence-based claims, selling products that are not approved by the FDA and issuing letters, said Associate Professor at University of Minnesota Leigh Turner. He praised the FDA for taking action.

He recently wrote a journal article called, Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed Stem Cell Treatments for COVID-19 in Cell Stem Cell.

These are basically companies that are entering the marketplace, charging thousands or tens of thousands of dollars for products where there's not a credible basis for the claims that are being made. When you go on the websites and see what sorts of statements are being made, they're misleading they are deceptive, theyre persuasive and they're not backed by any kind of credible scientific reality, said Tuner.

FDA said theyre working to find a vaccine and drugs that will prevent and treat COVID-19 as quickly as possible and offered some tips on how to identify false or misleading claims.

They said be suspicious of products that claim to treat a wide range of diseases and said personal testimonials are no substitute for scientific evidence.

They said few diseases or conditions can be treated quickly, so be suspicious of a quick fix," and miracle cures, which claim scientific breakthroughs or contain secret ingredients, are likely a hoax.

Turner said many products are just a waste of money and useless, however some could potentially cause harm to humans.

The FDA wants you to report any suspicious products you find online click here to do that.

Consumer Update: Beware of Fraudulent Coronavirus Tests, Vaccines and Treatments

List of Warning Letters for Fraudulent Coronavirus Disease 2019 (COVID-19) Products

Read the rest here:
FDA warns businesses to stop claiming to prevent, treat and diagnose COVID-19 - wtkr.com

Perceptive fields SPAC #3 as another group of biotechs scoops up $364M in latest Nasdaq romp – Endpoints News

Theres no sign that the windfall of cash dropping biotechs way on Wall Street is abating. Three more biopharmas priced IPOs on Thursday and Friday morning, riding a historic boom with a $364 million payoff.

London-based biotech Freeline Therapeutics took home the lions share of the cash with $159 million after pricing 8,823,529 shares at $18 a pop. Checkmate Pharmaceuticals, of Cambridge, MA, raised $75 million with an offer of 5 million shares at $15 right at the midpoint of its range. And Arya Sciences Acquisition Corp III, the third in a series from Perceptive, priced 13,000,000 shares at $10 per share.

Drugmakers are securing big sums amid the pandemic boom, including AlloVir, which bagged $276 million from 16.3 million shares last week. Initially, the company had filed for a $100 million IPO.By June, all 23 newly public companies had priced above their midpoint or upsized their offering.

And theres more coming: Kymera Therapeutics announced plans to go public on Monday, when it filed for a $100 million IPO.

Checkmate initially filed for an IPO on July 17, then raised its maximum offering price to $92 million in an amended S-1 filing. The immuno-oncology biotech is investigating its drug CMP-001 across multiple cancers, including melanoma and head and neck squamous cell carcinoma (HNSCC), and says it will use the funds to advance clinical trials. BofA Securities, Jefferies Group and BMO Capital Markets are managing the deal.

CMP-001 uses the immune system to its advantage, directing activated anti-tumor T cells to attack both the injected tumor and tumors throughout the body. Its been tested on more than 200 melanoma patients to date, and based on clinical data, the company believes there is an opportunity for CMP-001 to be developed as a differentiated immuno-oncology therapy, according to the S-1 filing.

Freeline initially filed for a $100 million IPO, with JP Morgan Securities LLC, Morgan Stanley & Co. and Evercore Group as joint bookrunners. Its AAV gene-therapy treatments target hemophilia A and B, Fabry disease, and Type 1 Gaucher disease.

The biotechs lead candidate, FLT180a, is currently in a Phase I/II trial for hemophilia B. IPO funds will propel the companys pipeline, including Phase I/II trials for FLT180a and FLT190, a potential drug to treat Fabry disease.

SPACs (special purpose acquisition companies) are benefiting from the boom, too. Once rare in the biotech world, they now represent nearly 35% of listings, Nasdaqs Jay Heller told Endpoints lastmonth.

Perceptive Advisors blank check company Arya III filed for a $143.7 million IPO on July 21, and investors are betting on a profitable merger. In March, Arya I merged with biotech Immatics in a $252 million deal. Cerevel Therapeutics merged with Arya II in July, expecting to raise about $445 million to develop its pipeline.

Go here to read the rest:
Perceptive fields SPAC #3 as another group of biotechs scoops up $364M in latest Nasdaq romp - Endpoints News